The drug or biologic administered is billed separately using the appropriate HCPCS Level II J-code (e.g., J0290 for ampicillin, J1040 for methylprednisolone, J0135 for adalimumab)
Encouraging safety and tolerability profile, with the majority of observed adverse events reported as mild or moderate
There were 81 participants that began the study, but 6 withdrew prior to completion
No other significant differences in oxytocin receptor density were observed in other high-expression brain regions, suggesting a specific upregulation of oxytocin receptors in the anterior cingulate cortex of MIA mice
In a 2018 analysis of clinical trial data, several researchers working with Novo Nordisk, the drugmaker for Ozempic and Wegovy, found that the drugs were safe and effective in adults over age 65, but noted that older adults reported discontinuation due to gastrointestinal issues at a higher rate than younger participants did
Target trial emulations of GLP-1 and dual GLP-1/GIP agonists to reduce major adverse liver outcomes in type 2 diabetes